InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical
company pioneering anti-inflammatory therapeutics targeting the
complement system, today announced financial results for the three
months ended March 31, 2024, and provided an operating update.
Prof. Niels C. Riedemann, Chief
Executive Officer and founder of InflaRx, commented:
“InflaRx made tremendous progress during the early months of 2024,
and is well positioned to advance vilobelimab and INF904 toward
meaningful clinical milestones. Our pivotal trial with vilobelimab
in PG continues to enroll patients, with an interim analysis
expected next year. Patients suffering from PG have no approved
treatment alternatives and often experience tremendous suffering.
Thus, PG remains an area of high unmet medical need and represents
a significant market opportunity for us. Phase I data for INF904
indicate best-in-class potential, and the possibility to address
multiple sizable unmet needs, spurring our plans to initiate Phase
IIa in CSU and HS by the end of this year. With our clear strategic
focus on immuno-dermatology, and the additional potential of our
drug candidates in the broader immunology inflammation field, we
are excited about the path ahead of us."
Virtual R&D event on June 5,
2024InflaRx will host a virtual research and development
event on June 5, 2024. Guided by internationally renowned thought
leaders, this event will focus on the planned development of
InflaRx’s new orally administered, low molecular weight C5aR
inhibitor, INF904, and the role of C5aR in CSU and HS. Discussions
will address underlying development rationales and expected Phase
IIa trial design, and provide insights into the commercial
opportunity. In addition, the event will cover INF904's broader
therapeutic potential in the immuno-inflammation field and recent
advances in our understanding of the role of C5a/C5aR signaling as
it relates to human inflammatory diseases.
Featured key opinion leaders will include
Prof. Dr. Marcus Maurer (Professor of Dermatology
and Allergology, Institute of Allergology, Charité –
Universitätsmedizin Berlin, Germany), Christopher Sayed,
MD (Prof. of Dermatology, University of North Carolina,
Medical School; and Secretary of the HS Foundation) and
Prof. Dr. Jörg Köhl (Director of the Institute for
Systemic Inflammation Research, University of Lübeck, Lübeck,
Germany). The meeting will take place on June 5, from 12:00 PM EDT
/ 6:00 PM CEST to 2:00 PM EDT / 8:00 PM CEST.
To participate in the virtual R&D event,
participants may pre-register here to receive a dedicated link and
dial-in details to access the meeting.
Capital One Securities Dermatology Panel
on May 14, 2024InflaRx will also participate in the
Capital One Securities 1st Annual Biotech/Biopharma Disrupters
Event, as a panelist on a panel, titled “New Potential Dermatology
Treatments for Psoriasis, Urticaria, and Alopecia” on May 14, 2024,
at 2:30 PM EDT / 8:30 PM CEST.
Recent Highlights and Business
Update
INF904 – Initial focus on CSU and HS,
broader opportunities in I&I possible via partneringIn
March 2024, InflaRx announced it had chosen two initial
immuno-dermatology indications it intends to pursue with INF904 and
that it plans to initiate a Phase IIa “basket study”. This
open-label, 4-week, multi-dose trial enrolling CSU and HS patients
is expected to begin by the end of 2024 and to assess safety, as
well as PK and PD parameters. InflaRx anticipates releasing data
from this Phase IIa study in 2025. Similarly, the company expects
to initiate a Phase IIb study in 2025 as well. InflaRx is currently
conducting additional pre-clinical studies, including chronic
toxicology studies, to enable longer-term dosing of INF904.
CSU and HS are two chronic inflammatory skin
conditions in which C5a has been suggested to play a significant
role and where a high unmet need exists. In addition, as an oral
drug with a mechanism of action currently not addressed by other
drugs in development for these indications, the company sees a
unique opportunity for INF904 to improve the standard of care.
INF904 - Positive topline results from
Phase I trial support best-in-class potentialIn January
2024, InflaRx reported results from the MAD part of a randomized,
double-blind, placebo-controlled Phase I trial in healthy
volunteers to assess the safety, tolerability and PK / PD
properties of its orally administered, low molecular weight C5aR
inhibitor, INF904. The safety analysis of INF904 in the Phase I
study demonstrated that it was well tolerated in participants over
the entire dose range and resulted in no safety signals of concern.
There were no serious or severe adverse events observed at any
dosing level. Both the single ascending dose and the MAD part of
the study showed favorable PK and PD profiles, including achieving
the desired blocking activity (>90%) of C5a-induced neutrophil
activation in an ex vivo challenge assay using physiological and
disease-relevant levels of C5a.
Vilobelimab in PG – Enrollment ongoing
in pivotal Phase III trialInflaRx is conducting a
multi-national, randomized, double-blind, placebo-controlled
pivotal Phase III study of vilobelimab for the treatment of
ulcerative PG, a rare, chronic inflammatory form of neutrophilic
dermatosis characterized by accumulation of neutrophils in the
affected skin areas. The trial has two arms: (1) vilobelimab plus a
low dose of corticosteroids and (2) placebo plus the same low dose
of corticosteroids. The primary endpoint of the study is complete
closure of the target ulcer at any time up to 26 weeks after
initiation of treatment.
The study has an adaptive design with an interim
analysis blinded for the sponsor and investigators planned upon
enrollment of approximately 30 patients (15 per arm). Depending on
the results of the interim analysis, expected to occur in 2025, the
trial sample size will be adapted, or the trial will be terminated
due to futility. The total enrollment period is projected to be at
least two years, depending on the total trial size after sample
size adaptation.
Vilobelimab has been granted orphan drug
designation for the treatment of PG by both the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA), as
well as fast track designation by the FDA.
GOHIBIC (vilobelimab) for the treatment
of critically ill COVID-19 patients – The InflaRx Commitment
Program launchedIn April, 2023, the FDA issued an
Emergency Use Authorization (EUA) for GOHIBIC (vilobelimab) for the
treatment of COVID-19 in hospitalized adults when initiated within
48 hours of receiving invasive mechanical ventilation (IMV) or
extracorporeal membrane oxygenation (ECMO). In January 2024,
InflaRx announced the launch of The InflaRx Commitment Program,
pursuant to which the cost of GOHIBIC (vilobelimab) will be
refunded for up to six (6) administered inpatient doses (the full
treatment course) to institutions that meet the eligibility
requirements*, for patients who were administered GOHIBIC
(vilobelimab) in line with its EUA and who died due to COVID-19 in
the intensive care unit.
InflaRx continues to explore funding options for
vilobelimab as a treatment for acute respiratory distress syndrome
(ARDS), including government grants as well as collaborations with
third parties.
The Marketing Authorization Application (MAA)
for the treatment of adult patients with SARS-CoV-2 induced septic
ARDS receiving IMV or ECMO is under regulatory review by the
European Committee for Medicinal Products for Human Use under the
centralized procedure, which applies to all 27 member states of the
European Union.
Vilobelimab abstract presentation at ATS
2024An InflaRx abstract titled “Vilobelimab in Combination
With Tocilizumab or Baricitinib Dramatically Improves Mortality in
Critically Ill COVID-19 Patients: A Subgroup Analysis” has been
accepted for presentation during a thematic poster session at the
American Thoracic Society 2024 International Conference on Tuesday,
May 21, from 11:30 AM PT / 2:30 PM ET / 8:30 PM CEST to 1:15 PM PT
/ 4:15 PM ET / 10:15 PM CEST.
Dr. Thomas Taapken, Chief Financial
Officer of InflaRx, said: “In the first quarter of 2024,
InflaRx strategically prioritized its efforts, focusing development
activities in a select number of immuno-dermatology indications.
Sharpening our profile in this way has helped put us in a strong
financial position, allowing us to advance our clinical programs
towards their next milestones and to fund operations at least into
2026.”
Financial Highlights – Q1
2024
RevenueFor the three months
ended March 31, 2024, we realized revenues from the product sales
of GOHIBIC (vilobelimab) in the amount of €36 thousand. Revenues
reported are sales to end customers (hospitals). Sales to
distributors do not constitute revenue for the InflaRx under IFRS
15. All revenues are attributed to sales made in the United
States.
Cost of salesThe cost of sales
during the three months ended March 31, 2024 mainly consists of
write-downs of inventories that will expire prior to their expected
sale.
Sales and marketing
expenses In the three months ended March 31, 2024, we
incurred €1.5 million of sales and marketing expenses. These
expenses are primarily comprised of €0.3 million in personnel costs
and €0.7 million in external services for distribution.
R&D expenses R&D
expenses incurred for the three months ended March 31, 2024
decreased by €7.4 million compared to the three months ended March
31, 2023. This decrease is primarily due to the fact that we
incurred high third-party expenses in the first quarter of 2023 in
connection with our efforts to develop the commercial manufacturing
process and to obtain an EUA for GOHIBIC (vilobelimab).
General and administrative
expenses General and administrative expenses amounted
to €3.6 million for each of the three months ended March 31, 2024
and March 31, 2023.
Other incomeOther income for
the three months ended March 31, 2024 amounted to €36 thousand (PY:
€7.7 million). The decrease of €7.7 million in other income is due
to the end of the government grant period on June 30, 2023.
Net financial result Net
financial result increased by €3.3 million to a gain of €2.8
million for the three months ended March 31, 2024 from a loss of
€0.5 million for the three months ended March 31, 2023. This
increase is mainly attributable to an increase of interest income
on marketable securities by €0.5 million and an increase of foreign
exchange result of €3.0 million. Other financial result consists of
an adjustment for expected credit losses on marketable
securities.
Net lossNet loss for the first
three months of 2024 amounted to €9.7 million, compared to €11.1
million in the first three months of 2023.
Net cash used in operating
activitiesNet cash used in operating activities for the
first three months of 2024 increased to €14.9 million from €10.5
million for the comparable period in 2023.
Liquidity and capital
resourcesAs of March 31, 2024, InflaRx’s total available
funds were approximately €85.8 million, composed of €25.1 million
in cash and cash equivalents and €60.7 million in marketable
securities. These funds are expected to finance operations at least
into 2026.
Additional financial
informationAdditional information regarding these results
and other relevant information is included in the notes to the
unaudited interim condensed consolidated financial statements as of
March 31, 2024, as well as the consolidated financial statements as
of and for the year ended December 31, 2023, in “ITEM 18. Financial
Statements,” in InflaRx’s Annual Report on Form 20-F for the year
ended December 31, 2023, as filed with the U.S. Securities and
Exchange Commission (SEC) on March 21, 2024.
InflaRx N.V. and
subsidiariesUnaudited condensed consolidated
statements of operations and comprehensive loss for the three
months ended March 31, 2024 and 2023
|
For the three months ended March
31, |
|
2024(unaudited) |
|
2023(unaudited) |
|
(in €, except for share data) |
|
|
Revenues |
36,037 |
|
|
— |
|
Cost of sales |
(220,521 |
) |
|
— |
|
Gross profit |
(184,484 |
) |
|
— |
|
Sales and marketing expenses |
(1,459,539 |
) |
|
— |
|
Research and development expenses |
(7,301,810 |
) |
|
(14,731,908 |
) |
General and administrative expenses |
(3,579,150 |
) |
|
(3,608,554 |
) |
Other income |
36,323 |
|
|
7,746,189 |
|
Other expenses |
(30 |
) |
|
(566 |
) |
Operating result |
(12,488,690 |
) |
|
(10,594,839 |
) |
Finance income |
908,426 |
|
|
456,036 |
|
Finance expenses |
(4,632 |
) |
|
(5,528 |
) |
Foreign exchange result |
1,824,375 |
|
|
(1,137,310 |
) |
Other financial result |
103,285 |
|
|
197,808 |
|
Income taxes |
— |
|
|
— |
|
Income (loss) for the period |
(9,657,236 |
) |
|
(11,083,833 |
) |
Other comprehensive income (loss) that may be reclassified to
profit or loss in subsequent periods: |
|
|
Exchange differences on translation of foreign currency |
(25,538 |
) |
|
(16,785 |
) |
Total comprehensive income (loss) |
(9,682,774 |
) |
|
(11,100,618 |
) |
|
|
|
Share information (based on income (loss) for the
period) |
|
|
Weighted average number of shares outstanding |
58,883,272 |
|
|
44,771,703 |
|
Income (loss) per share (basic/diluted) |
(0.17 |
) |
|
(0.25 |
) |
InflaRx N.V. and
subsidiariesUnaudited condensed consolidated
statements of financial position as of March 31, 2024 and
December 31, 2023
|
March 31, 2024(unaudited) |
|
December 31, 2023 |
|
(in €) |
ASSETS |
|
|
Non-current assets |
|
|
Property and equipment |
284,043 |
|
|
289,577 |
|
Right-of-use assets |
1,056,966 |
|
|
1,071,666 |
|
Intangible assets |
52,145 |
|
|
68,818 |
|
Other assets |
244,009 |
|
|
257,267 |
|
Financial assets |
2,490,202 |
|
|
9,052,741 |
|
Total non-current assets |
4,127,365 |
|
|
10,740,069 |
|
Current assets |
|
|
Inventories |
11,048,645 |
|
|
11,367,807 |
|
Current other assets |
5,869,744 |
|
|
4,036,650 |
|
Trade receivables |
35,242 |
|
|
— |
|
Tax receivable |
2,098,276 |
|
|
3,791,564 |
|
Other financial assets |
58,812,905 |
|
|
77,504,518 |
|
Cash and cash equivalents |
25,103,058 |
|
|
12,767,943 |
|
Total current assets |
102,967,870 |
|
|
109,468,483 |
|
TOTAL ASSETS |
107,095,235 |
|
|
120,208,552 |
|
|
|
|
EQUITY AND LIABILITIES |
|
|
Equity |
|
|
Issued capital |
7,065,993 |
|
|
7,065,993 |
|
Share premium |
334,211,338 |
|
|
334,211,338 |
|
Other capital reserves |
41,910,754 |
|
|
40,050,053 |
|
Accumulated deficit |
(295,785,055 |
) |
|
(286,127,819 |
) |
Other components of equity |
7,356,629 |
|
|
7,382,166 |
|
Total equity |
94,759,658 |
|
|
102,581,730 |
|
Non-current liabilities |
|
|
Lease liabilities |
727,058 |
|
|
745,716 |
|
Other liabilities |
36,877 |
|
|
36,877 |
|
Total non-current liabilities |
763,935 |
|
|
782,593 |
|
Current liabilities |
|
|
Trade and other payables |
7,607,757 |
|
|
11,974,362 |
|
Lease liabilities |
378,089 |
|
|
374,329 |
|
Employee benefits |
637,607 |
|
|
1,609,766 |
|
Other liabilities |
2,948,189 |
|
|
2,885,772 |
|
Total current liabilities |
11,571,642 |
|
|
16,844,229 |
|
Total liabilities |
12,335,557 |
|
|
17,626,822 |
|
TOTAL EQUITY AND LIABILITIES |
107,095,235 |
|
|
120,208,552 |
|
InflaRx N.V. and
subsidiariesUnaudited condensed consolidated
statements of changes in shareholders’ equity for the three months
ended March 31, 2024 and 2023
(in €) |
Issuedcapital |
|
Sharepremium |
|
Othercapitalreserves |
|
Accumulateddeficit |
|
Other componentsof equity |
|
Total equity |
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
7,065,993 |
|
334,211,338 |
|
40,050,053 |
|
(286,127,819 |
) |
|
7,382,166 |
|
|
102,581,730 |
|
Loss for the period |
— |
|
— |
|
— |
|
(9,657,236 |
) |
|
— |
|
|
(9,657,236 |
) |
Exchange differences on translation of foreign currency |
— |
|
— |
|
— |
|
— |
|
|
(25,538 |
) |
|
(25,538 |
) |
Total comprehensive loss |
— |
|
— |
|
— |
|
(9,657,236 |
) |
|
(25,538 |
) |
|
(9,682,774 |
) |
Equity-settled share-based payments |
— |
|
— |
|
1,860,701 |
|
— |
|
|
— |
|
|
1,860,701 |
|
Balance as of March 31, 2024 |
7,065,993 |
|
334,211,338 |
|
41,910,754 |
|
(295,785,055 |
) |
|
7,356,629 |
|
|
94,759,658 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2023 |
5,364,452 |
|
282,552,633 |
|
36,635,564 |
|
(243,460,290 |
) |
|
7,257,081 |
|
|
88,349,440 |
|
Loss for the period |
— |
|
— |
|
— |
|
(11,083,833 |
) |
|
— |
|
|
(11,083,833 |
) |
Exchange differences ontranslation of foreign currency |
— |
|
— |
|
— |
|
— |
|
|
(16,785 |
) |
|
(16,785 |
) |
Total comprehensive loss |
— |
|
— |
|
— |
|
(11,083,833 |
) |
|
(16,785 |
) |
|
(11,100,618 |
) |
Equity-settled share-based payments |
— |
|
— |
|
1,207,048 |
|
— |
|
|
— |
|
|
1,207,048 |
|
Share options exercised |
8,548 |
|
115,399 |
|
— |
|
— |
|
|
— |
|
|
123,947 |
|
Balance as of March 31, 2023 |
5,373,000 |
|
282,668,032 |
|
37,842,612 |
|
(254,544,123 |
) |
|
7,240,295 |
|
|
78,579,816 |
|
InflaRx N.V. and
subsidiariesUnaudited condensed consolidated
statements of cash flows for the three months ended March 31, 2024
and 2023
|
For the three months ended March
31, |
|
2024(unaudited) |
|
2023(unaudited) |
|
(in €) |
Operating activities |
|
|
Loss for the period |
(9,657,236 |
) |
|
(11,083,833 |
) |
Adjustments for: |
|
|
Depreciation & amortization of property and equipment,
right-of-use assets and intangible assets |
123,949 |
|
|
147,969 |
|
Net finance income (expense) |
(2,831,454 |
) |
|
488,994 |
|
Share-based payment expense |
1,860,701 |
|
|
1,207,048 |
|
Net foreign exchange differences |
(119,126 |
) |
|
(106,793 |
) |
Changes in: |
|
|
Financial assets from government grants |
— |
|
|
(2,701,076 |
) |
Inventories |
319,162 |
|
|
— |
|
Trade receivables |
(35,242 |
) |
|
— |
|
Employee benefits |
(972,159 |
) |
|
(834,713 |
) |
Other assets |
(126,547 |
) |
|
7,515,105 |
|
Other liabilities |
62,417 |
|
|
15,986 |
|
Liabilities from government grants received |
— |
|
|
(5,033,779 |
) |
Trade and other payables |
(4,366,605 |
) |
|
(371,445 |
) |
Interest received |
875,990 |
|
|
245,971 |
|
Interest paid |
(2,214 |
) |
|
(5,627 |
) |
Net cash used in operating activities |
(14,868,364 |
) |
|
(10,516,193 |
) |
Investing activities |
|
|
Purchase of intangible assets, property and equipment |
(16,069 |
) |
|
(6,046 |
) |
Purchase of current financial assets |
(3,566,235 |
) |
|
(25,120,832 |
) |
Proceeds from the maturity of financial assets |
30,527,108 |
|
|
21,540,578 |
|
Net cash from/(used in) investing activities |
26,944,804 |
|
|
(3,586,300 |
) |
Financing activities |
|
|
Proceeds from exercise of share options |
— |
|
|
123,947 |
|
Repayment of lease liabilities |
(85,706 |
) |
|
(93,744 |
) |
Net cash from/(used in) financing activities |
(85,706 |
) |
|
30,202 |
|
Net increase/(decrease) in cash and cash equivalents |
11,990,733 |
|
|
(14,072,291 |
) |
Effect of exchange rate changes on cash and cash equivalents |
344,381 |
|
|
(95,814 |
) |
Cash and cash equivalents at beginning of period |
12,767,943 |
|
|
16,265,355 |
|
Cash and cash equivalents at end of period |
25,103,058 |
|
|
2,097,250 |
|
|
About InflaRxInflaRx GmbH
(Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned
subsidiaries of InflaRx N.V. (together, InflaRx).
InflaRx (Nasdaq: IFRX) is a biopharmaceutical
company pioneering anti-inflammatory therapeutics by applying its
proprietary anti-C5a and anti-C5aR technologies to discover,
develop and commercialize highly potent and specific inhibitors of
the complement activation factor C5a and its receptor C5aR. C5a is
a powerful inflammatory mediator involved in the progression of a
wide variety of inflammatory diseases. InflaRx’s lead product
candidate, vilobelimab, is a novel, intravenously delivered,
first-in-class, anti-C5a monoclonal antibody that selectively binds
to free C5a and has demonstrated disease-modifying clinical
activity and tolerability in multiple clinical studies in different
indications. InflaRx is also developing INF904, an orally
administered, small molecule inhibitor of the C5a receptor. InflaRx
was founded in 2007, and the group has offices and subsidiaries in
Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For
further information, please visit www.inflarx.com.
Contacts:
InflaRx N.V. |
MC Services AG |
Jan Medina, CFAVice President, Head of Investor RelationsEmail:
IR@inflarx.de |
Katja Arnold, Laurie Doyle, Dr. Regina LutzEmail:
inflarx@mc-services.eu Europe: +49 89-210 2280U.S.:
+1-339-832-0752 |
FORWARD-LOOKING STATEMENTSThis
press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential” or “continue,” among others. Forward-looking statements
appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other
things, the receptiveness of GOHIBIC (vilobelimab) as a treatment
for COVID-19 by COVID-19 patients and U.S. hospitals and related
treatment recommendations by medical/healthcare institutes and
other third-party organizations, our ability to successfully
commercialize and the receptiveness of GOHIBIC (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals or
our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage
and reimbursement for, estimated returns and return accruals for,
and clinical utility of GOHIBIC (vilobelimab) in its approved or
authorized indication or for vilobelimab and any other product
candidates, under an EUA and in the future if approved for
commercial use in the United States or elsewhere; our ability to
successfully implement The InflaRx Commitment Program, the success
of our future clinical trials for vilobelimab’s treatment of
COVID-19 and other debilitating or life-threatening inflammatory
indications, including PG, and any other product candidates
including INF904, and whether such clinical results will reflect
results seen in previously conducted pre-clinical studies and
clinical trials; the timing, progress and results of pre-clinical
studies and clinical trials of our product candidates and
statements regarding the timing of initiation and completion of
studies or trials and related preparatory work, the period during
which the results of the trials will become available, the costs of
such trials and our research and development programs generally;
our interactions with regulators regarding the results of clinical
trials and potential regulatory approval pathways, including
related to our MAA submission for vilobelimab and our BLA
submission for GOHIBIC (vilobelimab), and our ability to obtain and
maintain full regulatory approval of vilobelimab or GOHIBIC
(vilobelimab) for any indication; whether the FDA, the EMA or any
comparable foreign regulatory authority will accept or agree with
the number, design, size, conduct or implementation of our clinical
trials, including any proposed primary or secondary endpoints for
such trials; our expectations regarding the scope of any approved
indication for vilobelimab; our ability to leverage our proprietary
anti-C5a and C5aR technologies to discover and develop therapies to
treat complement-mediated autoimmune and inflammatory diseases; our
ability to protect, maintain and enforce our intellectual property
protection for vilobelimab and any other product candidates, and
the scope of such protection; our manufacturing capabilities and
strategy, including the scalability and cost of our manufacturing
methods and processes and the optimization of our manufacturing
methods and processes, and our ability to continue to rely on our
existing third-party manufacturers and our ability to engage
additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for
the finished product GOHIBIC (vilobelimab); our estimates of our
expenses, ongoing losses, future revenue, capital requirements and
our needs for or ability to obtain additional financing; our
ability to defend against liability claims resulting from the
testing of our product candidates in the clinic or, if approved,
any commercial sales; if any of our product candidates obtain
regulatory approval, our ability to comply with and satisfy ongoing
obligations and continued regulatory overview; our ability to
comply with enacted and future legislation in seeking marketing
approval and commercialization; our future growth and ability to
compete, which depends on our retaining key personnel and
recruiting additional qualified personnel; and our competitive
position and the development of and projections relating to our
competitors in the development of C5a and C5aR inhibitors or our
industry; and the risks, uncertainties and other factors described
under the heading “Risk Factors” in our periodic filings with the
SEC. These statements speak only as of the date of this press
release and involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De May 2023 a May 2024